Safety and Efficacy Study of Dysport RU and Glabellar Lines

• Status: Completed
• Trial end date: 2011-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

The primary objective is to assess the dose response versus placebo of a single treatment of Dysport RU (Dysport RU, Ready to Use, for injection), for the improvement in appearance of moderate to severe glabellar lines at maximum frown.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ipsen
• Treatments: abobotulinumtoxinA; Botulinum Toxins; Botulinum Toxins, Type A; incobotulinumtoxinA; onabotulinumtoxinA

Criteria

Inclusion Criteria:

• Female between 30 - 60 years of age

• Moderate to severe vertical glabellar lines at maximum frown at baseline

Exclusion Criteria:

• Silicone injections into the upper face

• Any prior treatment with fillers (e.g. collagen-type implants) skin abrasions or photorejuvenation within the previous 12 months

• Any planned facial cosmetic surgery during the study period

• A history of ablative skin resurfacing of the area to be treated during the study.